What is the share price of GlaxoSmithKline Pharmaceuticals Ltd (GLAXO) today?
The share price of GLAXO as on 27th June 2025 is ₹3439.60. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on GlaxoSmithKline Pharmaceuticals Ltd (GLAXO) share?
The past returns of GlaxoSmithKline Pharmaceuticals Ltd (GLAXO) share are- Past 1 week: 3.70%
- Past 1 month: 11.36%
- Past 3 months: 21.25%
- Past 6 months: 51.23%
- Past 1 year: 28.46%
- Past 3 years: 129.46%
- Past 5 years: 130.81%
What are the peers or stocks similar to GlaxoSmithKline Pharmaceuticals Ltd (GLAXO)?
The peers or stocks similar to GlaxoSmithKline Pharmaceuticals Ltd (GLAXO) include:What is the dividend yield % of GlaxoSmithKline Pharmaceuticals Ltd (GLAXO) share?
The current dividend yield of GlaxoSmithKline Pharmaceuticals Ltd (GLAXO) is 1.57.What is the market cap of GlaxoSmithKline Pharmaceuticals Ltd (GLAXO) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of GlaxoSmithKline Pharmaceuticals Ltd (GLAXO) is ₹58268.90 Cr as of 27th June 2025.What is the 52 week high and low of GlaxoSmithKline Pharmaceuticals Ltd (GLAXO) share?
The 52-week high of GlaxoSmithKline Pharmaceuticals Ltd (GLAXO) is ₹3515.70 and the 52-week low is ₹1921.What is the PE and PB ratio of GlaxoSmithKline Pharmaceuticals Ltd (GLAXO) stock?
The P/E (price-to-earnings) ratio of GlaxoSmithKline Pharmaceuticals Ltd (GLAXO) is 62.82. The P/B (price-to-book) ratio is 29.86.Which sector does GlaxoSmithKline Pharmaceuticals Ltd (GLAXO) belong to?
GlaxoSmithKline Pharmaceuticals Ltd (GLAXO) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy GlaxoSmithKline Pharmaceuticals Ltd (GLAXO) shares?
You can directly buy GlaxoSmithKline Pharmaceuticals Ltd (GLAXO) shares on Tickertape. Simply sign up, connect your demat account and place your order.
GlaxoSmithKline Pharmaceuticals Ltd
GLAXO Share Price
3,439.604.17% (+137.70)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
GLAXO Stock Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
GLAXO Performance & Key Metrics
GLAXO Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 62.82 | 29.86 | 1.57% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 36.34 | 6.56 | 0.83% |
67%
Analysts have suggested that investors can buy this stock
from 3 analysts
Price Upside
Earnings Growth
Rev. Growth
GLAXO Company Profile
GlaxoSmithKline Pharmaceuticals is a pharmaceutical company engaged in the business of manufacturing, distributing and trading in pharmaceuticals. The Company develops a range of products in pharmaceuticals, vaccines and consumer healthcare.
SUNPHARMA
PE Ratio
37.05
37.05
1Y Return
11.30%
11.30%
Buy Reco %
87.88
87.88
CIPLA
PE Ratio
23.02
23.02
1Y Return
1.45%
1.45%
Buy Reco %
74.19
74.19
TORNTPHARM
PE Ratio
59.18
59.18
1Y Return
20.55%
20.55%
Buy Reco %
76.00
76.00
DRREDDY
PE Ratio
19.14
19.14
1Y Return
4.32%
4.32%
Buy Reco %
55.17
55.17
ZYDUSLIFE
PE Ratio
21.83
21.83
1Y Return
7.11%
7.11%
Buy Reco %
46.43
46.43
GLAXO Sentiment Analysis
GLAXO Sentiment Analysis
New
Crisp summary & key insights to decode earnings calls instantly
GLAXO Stock Summary · February 2025
As the company embarks on its second century, it showcases a robust commitment to growth and innovation, particularly in biopharma healthcare, where it has reported an impressive 18% revenue increase and 33% EBITDA growth. Despite challenges in the broader Indian pharmaceutical market, strategic initiatives in pediatric vaccines and adult vaccination ecosystems are expected to drive future performance, with a focus on innovative product launches in oncology and specialty medicines. Management emphasizes operational efficiency, having stabilized margins and improved medical representative productivity through digital engagement. While navigating pricing controls and market dynamics, the company remains optimistic about its ability to sustain growth and enhance shareholder returns, reinforcing its market leadership and commitment to improving healthcare outcomes.
GLAXO Stock Growth Drivers
GLAXO Stock Growth Drivers
7Strong Financial Performance
The company reported an 18% increase in revenue, driven by double-digit growth across all business
Robust Growth in Key Segments
The company demonstrated strong volume growth in both its general medicines and pediatric vaccines segments,
GLAXO Stock Challenges
GLAXO Stock Challenges
4Employee Cost Challenges
The company has experienced a one-off impact in employee costs amounting to approximately 9 crores,
Revenue Volatility and Pricing Control
The company has faced revenue volatility over the past two years, primarily due to the
GLAXO Forecast
GLAXO Forecasts
Price
Revenue
Earnings
GLAXO Share Price Forecast
GLAXO Share Price Forecast
2025
Current
₹3,439.60
Baseline
Forecast for Jun 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
2025
Current
₹3,439.60
Baseline
Forecast for Jun 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
GLAXO Company Revenue Forecast
GLAXO Company Revenue Forecast
2025
Current
₹3.90
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹ Thousand cr.
2025
Current
₹3.90
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹ Thousand cr.
GLAXO Stock EPS (Earnings Per Share) Forecast
GLAXO Stock EPS (Earnings Per Share) Forecast
2025
Current
₹54.76
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
2025
Current
₹54.76
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
GLAXO
GLAXO
Income
Balance Sheet
Cash Flow
Annual Normal View
GLAXO Income Statement
GLAXO Income Statement
Annual Normal View
| Financial Year | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 3,029.71 | 2,943.80 | 3,279.21 | 3,850.20 | 3,143.70 | 4,700.86 | 3,365.83 | 3,595.99 | 3,899.83 | 3,899.83 | ||||||||||
Raw Materials | 1,314.38 | 1,299.24 | 1,332.46 | 1,343.30 | 1,294.88 | 1,340.62 | 1,215.92 | 1,398.25 | 1,345.00 | 2,571.85 | ||||||||||
| Power & Fuel Cost | 27.82 | 26.44 | 27.94 | 33.36 | 26.08 | 27.83 | 29.60 | 29.64 | 30.18 | |||||||||||
| Employee Cost | 483.01 | 523.40 | 537.20 | 628.55 | 616.16 | 610.23 | 594.99 | 624.39 | 579.70 | |||||||||||
| Selling & Administrative Expenses | 373.99 | 358.84 | 381.41 | 376.88 | 242.05 | 343.67 | 370.30 | 374.73 | 383.98 | |||||||||||
| Operating & Other expenses | 292.00 | 157.73 | 268.39 | 1,073.35 | 357.54 | 215.32 | 248.00 | 281.31 | 232.98 | |||||||||||
EBITDA | 538.51 | 578.15 | 731.81 | 394.76 | 606.99 | 2,163.19 | 907.02 | 887.67 | 1,327.99 | 1,327.98 | ||||||||||
| Depreciation/Amortization | 27.08 | 37.99 | 48.59 | 82.68 | 78.60 | 68.19 | 65.77 | 69.68 | 66.79 | 66.79 | ||||||||||
| PBIT | 511.43 | 540.16 | 683.22 | 312.08 | 528.39 | 2,095.00 | 841.25 | 817.99 | 1,261.20 | 1,261.19 | ||||||||||
| Interest & Other Items | 0.25 | 0.19 | 0.55 | 6.34 | 3.53 | 2.00 | 1.81 | 1.80 | 1.31 | 1.31 | ||||||||||
| PBT | 511.18 | 539.97 | 682.67 | 305.74 | 524.86 | 2,093.00 | 839.44 | 816.19 | 1,259.89 | 1,259.88 | ||||||||||
| Taxes & Other Items | 174.38 | 189.24 | 237.27 | 212.55 | 166.72 | 398.28 | 228.76 | 226.23 | 332.30 | 332.30 | ||||||||||
| Net Income | 336.80 | 350.73 | 445.40 | 93.19 | 358.14 | 1,694.72 | 610.68 | 589.96 | 927.59 | 927.58 | ||||||||||
| EPS | 19.88 | 20.70 | 26.29 | 5.50 | 21.14 | 100.04 | 36.05 | 34.83 | 54.76 | 54.75 | ||||||||||
| DPS | 15.00 | 17.50 | 20.00 | 40.00 | 30.00 | 90.00 | 32.00 | 32.00 | 54.00 | 44.00 | ||||||||||
| Payout ratio | 0.75 | 0.85 | 0.76 | 7.27 | 1.42 | 0.90 | 0.89 | 0.92 | 0.99 | 0.80 |
GLAXO Company Updates
GLAXO Stock Peers
GLAXO Past Performance & Peer Comparison
GLAXO Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| GlaxoSmithKline Pharmaceuticals Ltd | 62.82 | 29.86 | 1.57% |
| Sun Pharmaceutical Industries Ltd | 37.05 | 6.03 | 0.95% |
| Cipla Ltd | 23.02 | 3.88 | 1.06% |
| Torrent Pharmaceuticals Ltd | 59.18 | 16.49 | 0.96% |
GLAXO Stock Price Comparison
Compare GLAXO with any stock or ETFCompare GLAXO with any stock or ETF
GLAXO
GLAXO Holdings
GLAXO Shareholdings
GLAXO Promoter Holdings Trend
GLAXO Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
GLAXO Institutional Holdings Trend
GLAXO Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
GLAXO Shareholding Pattern
GLAXO Shareholding Pattern
GLAXO Shareholding History
GLAXO Shareholding History
Foreign Institutions
Mutual Funds Invested in GLAXO
Mutual Funds Invested in GLAXO
Mutual Fund Holding
Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock
In last 3 months, mutual fund holding of the company has almost stayed constant
Top 5 Mutual Funds holding GlaxoSmithKline Pharmaceuticals Ltd
| Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 0.2547% | Percentage of the fund’s portfolio invested in the stock 1.62% | Change in the portfolio weight of the stock over the last 3 months 0.30% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 20/53 (+8) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.0802% | Percentage of the fund’s portfolio invested in the stock 2.54% | Change in the portfolio weight of the stock over the last 3 months 2.54% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 31/89 (+3) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.0606% | Percentage of the fund’s portfolio invested in the stock 0.94% | Change in the portfolio weight of the stock over the last 3 months 0.94% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 32/44 (+10) |
Compare 3-month MF holding change on Screener
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases containing GLAXO stock
smallcases containing GLAXO stock
A smallcase is a basket of stocks/ETFs that represents an idea or theme.Diversify your risk and buy smallcases that have GlaxoSmithKline Pharmaceuticals Ltd
GLAXO Events
GLAXO Events
GLAXO Dividend Trend
No Trend In Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
GLAXO has shown inconsistent dividend trend over the last 5 years
Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation
Current dividend yield is 1.57%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹15.70 every year
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
GLAXO Dividend Trend
No Trend In Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
GLAXO has shown inconsistent dividend trend over the last 5 years
Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation
Current dividend yield is 1.57%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹15.70 every year
GLAXO Upcoming Dividends
GLAXO Upcoming Dividends
No upcoming dividends are available
GLAXO Past Dividends
GLAXO Past Dividends
Cash Dividend
Ex DateEx DateMay 30, 2025
Final
Final | Div/Share: ₹42.00
Dividend/Share
₹42.00
Ex DateEx Date
May 30, 2025
Cash Dividend
Ex DateEx DateNov 7, 2024
Special
Special | Div/Share: ₹12.00
Dividend/Share
₹12.00
Ex DateEx Date
Nov 7, 2024
Cash Dividend
Ex DateEx DateMay 31, 2024
Final
Final | Div/Share: ₹32.00
Dividend/Share
₹32.00
Ex DateEx Date
May 31, 2024
Cash Dividend
Ex DateEx DateJun 30, 2023
Final
Final | Div/Share: ₹32.00
Dividend/Share
₹32.00
Ex DateEx Date
Jun 30, 2023
Cash Dividend
Ex DateEx DateJul 7, 2022
Special
Special | Div/Share: ₹60.00
Dividend/Share
₹60.00
Ex DateEx Date
Jul 7, 2022
GLAXO Stock News & Opinions
GLAXO Stock News & Opinions
Articles & Videos
Corporate
GlaxoSmithKline Pharmaceuticals declare Quarterly Result
GlaxoSmithKline Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 1 August 2025.Powered by Capital Market - Live
2 days agoCapital Market - Live
Corporate
GlaxoSmithKline Pharmaceuticals fixes record date for final dividend
GlaxoSmithKline Pharmaceuticals has fixed 30 May 2025 as record date for determining entitlement of members to final dividend for the financial year ended 31st March 2025. The dividend, if approved, shall be paid on or after 30 June 2025. Powered by Capital Market - Live
1 month agoCapital Market - Live
Spotlight
GSK Pharma gains as Q4 PAT rises 35% YoY to Rs 260 cr; declares dividend of Rs 42/share
Profit before tax stood at Rs 354.90 crore, up 32.08% from Rs 268.71 crore in the same period last year. Total expenses declined 3.53% YoY to Rs 650.64 crore. Notably, the cost of materials consumed dropped 43.65% YoY to Rs 108.35 crore, while employee benefits expense fell 11.49% to Rs 152.97 crore. On a full-year basis, the company's net profit jumped 57.19% to Rs 919.06 crore on a 9.28% rise in revenue to Rs 3,723.49 crore in FY25 over FY24. Bhushan Akshikar, managing director of GlaxoSmithKline Pharmaceuticals, said, 'Our diversified portfolio of general medicines, specialty, and vaccines has shown improved growth due to sustained innovation, enhanced healthcare professional (HCP) engagement, and rapid digital acceleration. This has enhanced reach, expanded coverage, and provided a seamless omnichannel experience for our customers. Our key brands, including Augmentin, Calpol, Ceftum, T-Bact, and Trelegy, have played a significant role in driving growth throughout the year. Shingrix is experiencing increased adoption, driven by heightened awareness and our efforts to develop the adult vaccination ecosystem in the country.' The company said it is on track to launch Zejula (Niraparib), a PARP inhibitor for ovarian cancer, and Jemperli (Dostarlimab), an immunotherapy for second-line treatment of endometrial cancer. Meanwhile, the board recommended a final dividend of Rs 42 per equity share for FY25, subject to shareholder approval at the company's 100th Annual General Meeting. GlaxoSmithKline Pharmaceuticals is a subsidiary of GlaxoSmithKline plc, one of the world's leading research-based pharmaceutical and healthcare companies.Powered by Capital Market - Live
1 month agoCapital Market - Live
Earnings
Glaxosmithkline Pharmaceuticals consolidated net profit rises 35.17% in the March 2025 quarter
Net profit of Glaxosmithkline Pharmaceuticals rose 35.17% to Rs 262.87 crore in the quarter ended March 2025 as against Rs 194.48 crore during the previous quarter ended March 2024. Sales rose 4.79% to Rs 974.37 crore in the quarter ended March 2025 as against Rs 929.80 crore during the previous quarter ended March 2024. For the full year,net profit rose 57.23% to Rs 927.58 crore in the year ended March 2025 as against Rs 589.96 crore during the previous year ended March 2024. Sales rose 8.56% to Rs 3749.21 crore in the year ended March 2025 as against Rs 3453.71 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales974.37929.80 5 3749.213453.71 9 OPM %34.2027.67 -31.4026.31 - PBDT373.29286.32 30 1321.981029.48 28 PBT358.57268.22 34 1255.19959.80 31 NP262.87194.48 35 927.58589.96 57 Powered by Capital Market - Live
1 month agoCapital Market - Live
Earnings
Glaxosmithkline Pharmaceuticals standalone net profit rises 34.73% in the March 2025 quarter
Net profit of Glaxosmithkline Pharmaceuticals rose 34.73% to Rs 260.14 crore in the quarter ended March 2025 as against Rs 193.08 crore during the previous quarter ended March 2024. Sales rose 6.06% to Rs 966.08 crore in the quarter ended March 2025 as against Rs 910.87 crore during the previous quarter ended March 2024. For the full year,net profit rose 57.19% to Rs 919.06 crore in the year ended March 2025 as against Rs 584.69 crore during the previous year ended March 2024. Sales rose 9.28% to Rs 3723.49 crore in the year ended March 2025 as against Rs 3407.25 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales966.08910.87 6 3723.493407.25 9 OPM %34.2428.03 -31.4026.43 - PBDT369.62284.41 30 1310.541022.33 28 PBT354.90266.31 33 1243.75952.65 31 NP260.14193.08 35 919.06584.69 57 Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
Board of GlaxoSmithKline Pharmaceuticals recommends final dividend
GlaxoSmithKline Pharmaceuticals announced that the Board of Directors of the Company at its meeting held on 13 May 2025, inter alia, have recommended the final dividend of Rs 42 per equity Share (i.e. 420%) , subject to the approval of the shareholders.Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
GlaxoSmithKline Pharmaceuticals AGM scheduled
GlaxoSmithKline Pharmaceuticals announced that the Annual General Meeting(AGM) of the company will be held on 27 June 2025.Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
GlaxoSmithKline Pharmaceuticals to conduct board meeting
GlaxoSmithKline Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 13 May 2025.Powered by Capital Market - Live
2 months agoCapital Market - Live
Earnings
Glaxosmithkline Pharmaceuticals consolidated net profit rises 402.80% in the December 2024 quarter
Net profit of Glaxosmithkline Pharmaceuticals rose 402.80% to Rs 229.88 crore in the quarter ended December 2024 as against Rs 45.72 crore during the previous quarter ended December 2023. Sales rose 17.90% to Rs 949.42 crore in the quarter ended December 2024 as against Rs 805.26 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales949.42805.26 18 OPM %30.7527.08 - PBDT326.90245.85 33 PBT308.10228.74 35 NP229.8845.72 403 Powered by Capital Market - Live
4 months agoCapital Market - Live
Spotlight
Glaxosmithkline Pharmaceuticals Ltd leads gainers in 'A' group
Spandana Sphoorty Financial Ltd, Reliance Power Ltd, Fusion Finance Ltd and Aarti Pharmalabs Ltd are among the other gainers in the BSE's 'A' group today, 06 February 2025.Glaxosmithkline Pharmaceuticals Ltd soared 7.88% to Rs 2148.8 at 11:48 IST. The stock was the biggest gainer in the BSE's 'A' group. On the BSE, 8603 shares were traded on the counter so far as against the average daily volumes of 4008 shares in the past one month. Spandana Sphoorty Financial Ltd spiked 7.44% to Rs 351.75. The stock was the second biggest gainer in 'A' group. On the BSE, 50402 shares were traded on the counter so far as against the average daily volumes of 1.73 lakh shares in the past one month. Reliance Power Ltd surged 7.07% to Rs 42.71. The stock was the third biggest gainer in 'A' group. On the BSE, 66.83 lakh shares were traded on the counter so far as against the average daily volumes of 32.11 lakh shares in the past one month. Fusion Finance Ltd rose 6.35% to Rs 185.8. The stock was the fourth biggest gainer in 'A' group. On the BSE, 40400 shares were traded on the counter so far as against the average daily volumes of 39721 shares in the past one month. Aarti Pharmalabs Ltd gained 6.34% to Rs 678. The stock was the fifth biggest gainer in 'A' group. On the BSE, 3.11 lakh shares were traded on the counter so far as against the average daily volumes of 25140 shares in the past one month. Powered by Capital Market - Live
4 months agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 1.86%, vs industry avg of 9.02%
Over the last 5 years, market share decreased from 1.49% to 0.94%
Over the last 5 years, net income has grown at a yearly rate of 5.78%, vs industry avg of 15.29%